Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Peptone logo — Drugging disordered proteins with physics and AI

Peptone

Drugging disordered proteins with physics and AI

Founded 2018 United Kingdom London, United Kingdom 45 employees Series A Total: $42.00M Biotechnology, Pharmaceutical

General Information

Company Name Peptone
Founded Year 2018
Location United Kingdom London, United Kingdom
Employees 45
Industries Biotechnology, Pharmaceutical
Funding Stage Series A
Business Model B2B, SaaS, B2B2B
Revenue Model Licensing, Service Fee, Project Based
Social

BounceWatch is an independent company data service, not affiliated with Peptone. To contact Peptone, visit peptone.io.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Peptone compare?

A PDF of Peptone and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Peptone soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Peptone

Peptone, founded in 2018, is a pioneering player in the Biotechnology and Pharmaceutical sectors, headquartered in the United Kingdom. Leveraging a unique combination of AI and experimental physics, Peptone has developed a product engine aimed at designing small molecules that can target the 6,200 intrinsically disordered proteins previously unmodelable by Alpha Fold 3.

With its slogan, "Drugging disordered proteins with physics and AI," the company addresses a significant gap in the drug discovery field. This innovative approach positions Peptone at the forefront of new therapeutic developments, targeting a challenging class of proteins with high medical relevance.

Peptone last attracted a $40.00M Series A investment on 09 June 2022, showcasing strong support from leading investors including Bessemer Venture Partners, F-Prime Capital, Hoxton Ventures, Walden Catalyst, and dRx Capital. This backing underscores investor confidence in the company's innovative strategy and potential impact on the pharmaceutical industry.

Business keywords: therapeutics, experimental physics, small molecule design, intrinsically disordered proteins, biophysics, pre-clinical research, translational medicine, novel therapeutics discovery, high performance computing, structural biology, supercomputers

Services & Products

Development of small-molecule drug candidates
Protein dynamics mapping
AI-driven drug design
Experimental and translational biology integration

Target Customers

Pharmaceutical companies Biotechnology firms Oncology researchers Healthcare providers focused on hard-to-treat cancers

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $40.00M 5
Bessemer Venture Partners F-Prime Capital Hoxton Ventures
Bessemer Venture Partners, F-Prime Capital +3
09 Jun 2022
Seed Round €2.00M 4
Founders Factory Hoxton Ventures dRx Capital
Founders Factory, Hoxton Ventures +2
08 Jan 2021

Latest News

View All
Hussein Kanji: 'We could’ve been an exceptional fund if we’d been a little bit more disciplined abou... — Sifted
Hussein Kanji: 'We could’ve been an exceptional fund if we’d been a little bit more disciplined about selling'
Sifted Nov 23, 2025

Peptone Alternatives & Competitors

View All Alternatives
Peptone vs
Avilar Therapeutics
Avilar Therapeutics United States

Pioneering the discovery and development of extracellular protein degraders.

Seed
25 employees
Biotechnology, Pharmaceutical
Compare Peptone vs Avilar Therapeutics
Peptone vs
Congruence Therapeutics
Congruence Therapeutics Canada

From Topology to Treatments.

44 employees
Biotechnology, Pharmaceutical
Compare Peptone vs Congruence Therapeutics
Peptone vs
FogPharma
FogPharma United States

Until everything is druggable.

Series E
146 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Peptone

Drugging disordered proteins with physics and AI
Peptone was founded in 2018.
Peptone is headquartered in London, United Kingdom.
Peptone operates in Biotechnology and Pharmaceutical. Its work centres on therapeutics, experimental physics, small molecule design and intrinsically disordered proteins. Its customers include Pharmaceutical companies, Biotechnology firms and Oncology researchers.
Peptone has a B2B, SaaS and B2B2B business model. Its revenue comes from Licensing, Service Fee and Project Based.
Peptone has approximately 45 employees.
Peptone has completed 2 funding rounds, raising a total of $42.00M. The latest funding stage is Series A.
Peptone offers: Development of small-molecule drug candidates, Protein dynamics mapping, AI-driven drug design, Experimental and translational biology integration.
Top alternatives and competitors to Peptone include Avilar Therapeutics, Congruence Therapeutics, FogPharma, Sibylla Biotech, Frontier Medicines. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Peptone and Avilar Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Peptone, https://bouncewatch.com/company/peptone, updated 5 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout